![Per-Oluf Olsen](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Per-Oluf Olsen
Director/Board Member at Nextera AS
Network origin in Per-Oluf Olsen first degree
Entity | Entity type | Industry | |
---|---|---|---|
Nextera AS
![]() Nextera AS Miscellaneous Commercial ServicesCommercial Services Nextera AS provides drug research for therapeutic interventions for autoimmune diseases, chronic infections, and cancer. It offers platform for protein engineering and evolution, such as life sciences, drug discovery, and lead optimization fields. The firm’s core competence lies within protein engineering and evolution utilizing its technology to epitope discovery and epitope validation, as well as lead-candidate generation and validation in-vitro. The company was founded by Geir Åge Løset and Inger Sandlie in 2009 and is headquartered in Oslo, Norway.
5
| Holding Company | Miscellaneous Commercial Services | 5 |
Birk Venture AS
![]() Birk Venture AS Investment ManagersFinance Birk Venture AS (Birk Venture) is an independent Scandinavian venture capital firm which was founded in 2010 by Hans Ivar Robinson. Based in Oslo, Norway, the firm focuses exclusively on the life science industry, utilizing their industry experience and international network to partner with young companies with significant growth prospects.
1
| Subsidiary | Investment Managers | 1 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Per-Oluf Olsen via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
Oslo Cancer Cluster NCE
![]() Oslo Cancer Cluster NCE Miscellaneous Commercial ServicesCommercial Services Oslo Cancer Cluster NCE is an oncology research firm that specializes in developing cancer diagnostics and medicines. The private company is based in Oslo, Norway. | Miscellaneous Commercial Services | Director/Board Member | |
PHOTOCURE ASA | Medical Specialties | Director/Board Member | |
BIOINVENT INTERNATIONAL AB | Biotechnology | Chief Executive Officer | |
AstraZeneca AS | Corporate Officer/Principal | ||
Radiumhospitalets Forskningsstiftelse
![]() Radiumhospitalets Forskningsstiftelse Financial ConglomeratesFinance Radiumhospitalets Forskningsstiftelse invests in companies from Nordic research institutions. It is a pre-seed investor and project developer focused on cancer. It strengthens cancer research at Rikshospitalet University Hospital, including The Norwegian Radium Hospital. It provides Oslo Cancer Cluster with the necessary infrastructure and management team, as well. The company was founded in 1986 and is headquartered in Lysaker, Norway. | Financial Conglomerates | Chief Investment Officer | |
AstraZeneca AB
![]() AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Miscellaneous Commercial Services | Sales & Marketing | |
University of Oslo | College/University | Doctorate Degree Undergraduate Degree | |
Norwegian School of Economics & Business Administration | College/University | Graduate Degree | |
University of Bielefeld | College/University | Doctorate Degree | |
BI Norwegian Business School | College/University | Graduate Degree Graduate Degree | |
Ernst & Young AS
![]() Ernst & Young AS Miscellaneous Commercial ServicesCommercial Services Part of Ernst & Young Global Ltd., Ernst & Young AS is a Norwegian company that provides accounting services. The company is based in Oslo, Norway. The CEO of the company is Christin Erichsen Bøsterud. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Uni Targeting Research AS
![]() Uni Targeting Research AS BiotechnologyHealth Technology Uni Targeting Research AS is a holding company that provides the biopharmaceutical industry with tools and services for mammalian cell-line based development procedures and production processes. It offers upstream solutions to reduce complementary deoxyribonucleic acid and mammalian cell-line based timelines and increase protein production yields. Its technology enables both enhanced synthesis/secretion of naturally secreted proteins, and secretion of intracellular proteins. Its services include vector improvement, tailor-made vectors, and tool proteins. The company was founded by Ian Fraser Pryme, John E. Hesketh, Albert Tauler, and Beate Stern in 2001 and is headquartered in Bergen, Norway. | Biotechnology | Director/Board Member | |
Opsona Therapeutics Ltd.
![]() Opsona Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland. | Pharmaceuticals: Major | Chief Executive Officer | |
NYKODE THERAPEUTICS | Pharmaceuticals: Major | Chairman | |
Pfizer AS
![]() Pfizer AS Pharmaceuticals: MajorHealth Technology Pfizer AS operates as biopharmaceutical company, which engages in the development and manufacture of pharmaceutical products. It develops and produces medicines such as penicillin; vaccines; and medicines for the treatment of cancer, pain, cardiovascular disease, diabetes, mental illness, and rheumatism. The firm also offers drugs against parasites. The company was founded on November 25, 1959 and is headquartered in Oslo, Norway. | Pharmaceuticals: Major | Corporate Officer/Principal | |
BERGENBIO ASA | Pharmaceuticals: Major | Director/Board Member | |
APIM Therapeutics AS
![]() APIM Therapeutics AS Pharmaceuticals: MajorHealth Technology APIM Therapeutics AS develops and commercializes novel anti-cancer therapies. It offers a physiological intervention point allowing the potentiation of the action of clinical drugs across multiple cancer indications. The company focuses on the development and commercialization of novel anti-cancer therapies potentiating chemo-therapy induced responses in cancer cells. The company was founded by Marit Otterlei in 2009 and is headquartered in Trondheim, Norway. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
ExpreS2ion Biotechnologies ApS
![]() ExpreS2ion Biotechnologies ApS BiotechnologyHealth Technology ExpreS2ion Biotechnologies ApS operates as a biotechnology company which engages in the field of protein production in Drosophila Schneider-2 cells. Its services include custom proteins and research & development reagents, process development, and feasibility studies. The company was founded by Charlotte Dyring, Martin Roland Jensen, and Willem Adriaan de Jongh in 2009 and is headquartered in Horsholm, Denmark. | Biotechnology | Director/Board Member | |
CIRCIO HOLDING ASA | Biotechnology | Director/Board Member | |
Zelluna Immunotherapy AS
![]() Zelluna Immunotherapy AS BiotechnologyHealth Technology Zelluna Immunotherapy AS engages in research and development on biotechnology. The company is headquartered in Oslo, Norway. | Biotechnology | Director/Board Member Founder Director/Board Member | |
Nucligen AS | Director/Board Member | ||
Radforsk | Chief Investment Officer | ||
Accession Therapeutics Limited
![]() Accession Therapeutics Limited BiotechnologyHealth Technology Accession Therapeutics Limited is a British biotech company that is developing novel immuno-oncology therapeutics to eradicate cancers by harnessing the immune system more powerfully than ever before. The company is based in Oxford, UK and was founded in 2020 by Bent K. Jakobsen, who has been the CEO since then. The company's product, Trocept, is the first approach that meets the three requirements of being highly specific, broad in action to kill all cancer cell variants present, and potent in activating the full immune system arsenal local to the tumour. The team is built around successful biotech entrepreneurs experienced in taking projects through to the clinic and is supported by a Board comprising experienced international healthcare investors. | Biotechnology | Director/Board Member | |
Artbio AS
![]() Artbio AS BiotechnologyHealth Technology Part of Artbio, Inc., Artbio AS is a clinical-stage radiopharmaceutical biotechnology business that works to create a new class of alpha radio ligand medicines. The company is based in Oslo, Norway. The Norwegian company was founded in 2018. The CEO is Emanuele Ostuni. | Biotechnology | Director/Board Member |
Statistics
International
Norway | 22 |
Sweden | 3 |
Germany | 3 |
Denmark | 3 |
United States | 2 |
Sectoral
Health Technology | 17 |
Commercial Services | 6 |
Consumer Services | 5 |
Finance | 2 |
Technology Services | 2 |
Operational
Director/Board Member | 17 |
Corporate Officer/Principal | 8 |
Chief Executive Officer | 7 |
Chairman | 6 |
Founder | 5 |
Most connected contacts
Insiders | |
---|---|
Martin Welschof | 12 |
Anders Tuv | 12 |
Hans Ivar Robinson | 11 |
Thomas Andersen | 5 |
Geir Åge Løset | 3 |
- Stock Market
- Insiders
- Per-Oluf Olsen
- Company connections